drugset / Trial / NCT02273518

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

NCT02273518

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Comparative pharmacokinetics of dipyridamole in two new formulations of Asasantin ER compared to the present commercial formulation

Timeline

Start
2001-04
Primary completion
2001-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ASA Unknown 25 mg
Subject Dipyridamole Other / unclassified 200 mg

Indications

No indication recorded.